vs
Mativ Holdings, Inc.（MATV）与Royalty Pharma plc（RPRX）财务数据对比。点击上方公司名可切换其他公司
Royalty Pharma plc的季度营收约是Mativ Holdings, Inc.的1.3倍（$622.0M vs $463.1M），Royalty Pharma plc净利率更高（34.4% vs 21.8%，领先12.7%），Royalty Pharma plc同比增速更快（4.8% vs 1.0%），过去两年Royalty Pharma plc的营收复合增速更高（4.6% vs -3.8%）
Mativ Holdings是一家全球特种材料制造商，主要生产高性能先进聚合物、无纺布、过滤解决方案及功能性涂层材料，服务医疗、工业、消费品、航空航天、能源等领域，业务遍及北美、欧洲及亚太地区。
本公司是总部位于美国马萨诸塞州剑桥市的临床阶段生物制药企业，专注于研发可调节转化生长因子β（TGF-β）超家族蛋白的药物，该类蛋白在红细胞、肌肉、骨骼、血管等细胞与组织的生长修复过程中发挥核心作用。
MATV vs RPRX — 直观对比
营收规模更大
RPRX
是对方的1.3倍
$463.1M
营收增速更快
RPRX
高出3.8%
1.0%
净利率更高
RPRX
高出12.7%
21.8%
两年增速更快
RPRX
近两年复合增速
-3.8%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $463.1M | $622.0M |
| 净利润 | $100.8M | $214.2M |
| 毛利率 | 18.8% | — |
| 营业利润率 | 2.2% | 62.4% |
| 净利率 | 21.8% | 34.4% |
| 营收同比 | 1.0% | 4.8% |
| 净利润同比 | 6620.0% | 2.9% |
| 每股收益（稀释后） | $1.87 | $0.49 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MATVRPRX
| Q4 25 | $463.1M | $622.0M | ||
| Q3 25 | $513.7M | $609.3M | ||
| Q2 25 | $525.4M | $578.7M | ||
| Q1 25 | $484.8M | $568.2M | ||
| Q4 24 | $458.6M | $593.6M | ||
| Q3 24 | $498.5M | $564.7M | ||
| Q2 24 | $523.8M | $537.3M | ||
| Q1 24 | $500.2M | $568.0M |
净利润MATVRPRX
| Q4 25 | $100.8M | $214.2M | ||
| Q3 25 | $-3.2M | $288.2M | ||
| Q2 25 | $-9.5M | $30.2M | ||
| Q1 25 | $-425.5M | $238.3M | ||
| Q4 24 | $1.5M | $208.2M | ||
| Q3 24 | $-20.8M | $544.0M | ||
| Q2 24 | $-1.4M | $102.0M | ||
| Q1 24 | $-28.0M | $4.8M |
毛利率MATVRPRX
| Q4 25 | 18.8% | — | ||
| Q3 25 | 19.3% | — | ||
| Q2 25 | 19.7% | — | ||
| Q1 25 | 15.0% | — | ||
| Q4 24 | 16.9% | — | ||
| Q3 24 | 18.8% | — | ||
| Q2 24 | 20.8% | — | ||
| Q1 24 | 16.8% | — |
营业利润率MATVRPRX
| Q4 25 | 2.2% | 62.4% | ||
| Q3 25 | 3.1% | 70.1% | ||
| Q2 25 | 3.8% | 36.3% | ||
| Q1 25 | -88.8% | 94.0% | ||
| Q4 24 | 0.6% | 60.9% | ||
| Q3 24 | 1.4% | — | ||
| Q2 24 | 2.0% | 50.2% | ||
| Q1 24 | -2.8% | -13.0% |
净利率MATVRPRX
| Q4 25 | 21.8% | 34.4% | ||
| Q3 25 | -0.6% | 47.3% | ||
| Q2 25 | -1.8% | 5.2% | ||
| Q1 25 | -87.8% | 41.9% | ||
| Q4 24 | 0.3% | 35.1% | ||
| Q3 24 | -4.2% | 96.3% | ||
| Q2 24 | -0.3% | 19.0% | ||
| Q1 24 | -5.6% | 0.8% |
每股收益（稀释后）MATVRPRX
| Q4 25 | $1.87 | $0.49 | ||
| Q3 25 | $-0.06 | $0.67 | ||
| Q2 25 | $-0.18 | $0.07 | ||
| Q1 25 | $-7.82 | $0.55 | ||
| Q4 24 | $0.03 | $0.46 | ||
| Q3 24 | $-0.38 | $1.21 | ||
| Q2 24 | $-0.03 | $0.23 | ||
| Q1 24 | $-0.52 | $0.01 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $84.2M | $618.7M |
| 总债务越低越好 | $1.0B | $9.0B |
| 股东权益账面价值 | $498.7M | $9.7B |
| 总资产 | $2.1B | $19.6B |
| 负债/权益比越低杠杆越低 | 2.07× | 0.92× |
8季度趋势，按日历期对齐
现金及短期投资MATVRPRX
| Q4 25 | $84.2M | $618.7M | ||
| Q3 25 | $97.1M | $938.9M | ||
| Q2 25 | $95.6M | $631.9M | ||
| Q1 25 | $84.0M | $1.1B | ||
| Q4 24 | $94.3M | $929.0M | ||
| Q3 24 | $162.2M | $950.1M | ||
| Q2 24 | $133.4M | $1.8B | ||
| Q1 24 | $128.9M | $843.0M |
总债务MATVRPRX
| Q4 25 | $1.0B | $9.0B | ||
| Q3 25 | $1.0B | $8.9B | ||
| Q2 25 | $1.1B | $8.0B | ||
| Q1 25 | $1.1B | $7.6B | ||
| Q4 24 | $1.1B | $7.6B | ||
| Q3 24 | $1.2B | $7.6B | ||
| Q2 24 | $1.2B | $7.6B | ||
| Q1 24 | $1.2B | $6.1B |
股东权益MATVRPRX
| Q4 25 | $498.7M | $9.7B | ||
| Q3 25 | $397.4M | $9.6B | ||
| Q2 25 | $416.6M | $9.5B | ||
| Q1 25 | $428.2M | $9.8B | ||
| Q4 24 | $858.5M | $10.3B | ||
| Q3 24 | $882.3M | $10.3B | ||
| Q2 24 | $898.0M | $9.8B | ||
| Q1 24 | $906.9M | $9.9B |
总资产MATVRPRX
| Q4 25 | $2.1B | $19.6B | ||
| Q3 25 | $2.0B | $19.3B | ||
| Q2 25 | $2.1B | $18.3B | ||
| Q1 25 | $2.1B | $17.6B | ||
| Q4 24 | $2.4B | $18.2B | ||
| Q3 24 | $2.6B | $18.0B | ||
| Q2 24 | $2.6B | $17.7B | ||
| Q1 24 | $2.7B | $16.1B |
负债/权益比MATVRPRX
| Q4 25 | 2.07× | 0.92× | ||
| Q3 25 | 2.63× | 0.93× | ||
| Q2 25 | 2.66× | 0.84× | ||
| Q1 25 | 2.67× | 0.78× | ||
| Q4 24 | 1.30× | 0.74× | ||
| Q3 24 | 1.32× | 0.74× | ||
| Q2 24 | 1.29× | 0.78× | ||
| Q1 24 | 1.30× | 0.62× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $19.3M | $827.1M |
| 自由现金流经营现金流 - 资本支出 | $8.0M | — |
| 自由现金流率自由现金流/营收 | 1.7% | — |
| 资本支出强度资本支出/营收 | 2.4% | — |
| 现金转化率经营现金流/净利润 | 0.19× | 3.86× |
| 过去12个月自由现金流最近4个季度 | $93.8M | — |
8季度趋势，按日历期对齐
经营现金流MATVRPRX
| Q4 25 | $19.3M | $827.1M | ||
| Q3 25 | $72.8M | $702.6M | ||
| Q2 25 | $57.6M | $364.0M | ||
| Q1 25 | $-15.9M | $596.1M | ||
| Q4 24 | $24.1M | $742.5M | ||
| Q3 24 | $37.6M | $703.6M | ||
| Q2 24 | $46.1M | $658.2M | ||
| Q1 24 | $-13.0M | $664.6M |
自由现金流MATVRPRX
| Q4 25 | $8.0M | — | ||
| Q3 25 | $66.7M | — | ||
| Q2 25 | $48.9M | — | ||
| Q1 25 | $-29.8M | — | ||
| Q4 24 | $2.0M | — | ||
| Q3 24 | $25.5M | — | ||
| Q2 24 | $37.4M | — | ||
| Q1 24 | $-25.1M | — |
自由现金流率MATVRPRX
| Q4 25 | 1.7% | — | ||
| Q3 25 | 13.0% | — | ||
| Q2 25 | 9.3% | — | ||
| Q1 25 | -6.1% | — | ||
| Q4 24 | 0.4% | — | ||
| Q3 24 | 5.1% | — | ||
| Q2 24 | 7.1% | — | ||
| Q1 24 | -5.0% | — |
资本支出强度MATVRPRX
| Q4 25 | 2.4% | — | ||
| Q3 25 | 1.2% | — | ||
| Q2 25 | 1.7% | — | ||
| Q1 25 | 2.9% | — | ||
| Q4 24 | 4.8% | — | ||
| Q3 24 | 2.4% | — | ||
| Q2 24 | 1.7% | — | ||
| Q1 24 | 2.4% | — |
现金转化率MATVRPRX
| Q4 25 | 0.19× | 3.86× | ||
| Q3 25 | — | 2.44× | ||
| Q2 25 | — | 12.06× | ||
| Q1 25 | — | 2.50× | ||
| Q4 24 | 16.07× | 3.57× | ||
| Q3 24 | — | 1.29× | ||
| Q2 24 | — | 6.45× | ||
| Q1 24 | — | 139.10× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MATV
| Other | $208.7M | 45% |
| SAS Segment | $157.4M | 34% |
| FAM Segment | $97.0M | 21% |
RPRX
| Financial Royalty Assets | $592.4M | 95% |
| Royalty Income Other | $29.6M | 5% |
